Last reviewed · How we verify

NCT07049120

Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions

Not yet recruiting NA Last updated 3 July 2025
What this trial tests

NA trial testing ZENFLEX Pro™ Peripheral Drug-eluting Stent System in Peripheral Arterial Disease in 153 participants. Not yet recruiting.

Timeline
30 June 2025
Primary endpoint
31 May 2027
31 October 2027

Quick facts

Lead sponsorZhejiang Zylox Medical Device Co., Ltd.
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment153
Start date30 June 2025
Primary completion31 May 2027
Estimated completion31 October 2027
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Zhejiang Zylox Medical Device Co., Ltd.

Who can join

Adults 18 to 80, any sex, with Peripheral Arterial Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion. A total of 153 subjects will be followed at 1, 6, and 12 months. The primary endpoint is primary patency at 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

Other Zhejiang Zylox Medical Device Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07049120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing